Hormone substitution in male hypogonadism

Molecular and Cellular Endocrinology

Volumn 161, Issue 1-2, 2000, Pages 73-88

  Zitzmann, M ^a   Nieschlag, E ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

FSH; GnRH; Gonadotropins; hCG; hMG; LH; Male hypogonadism; Testosterone deficiency; Testosterone substitution

Indexed keywords

CHORIONIC GONADOTROPIN; FOLLITROPIN; GONADORELIN; GONADOTROPIN; HUMAN GROWTH HORMONE; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE; RECOMBINANT FOLLITROPIN; TESTOSTERONE; TESTOSTERONE 4 BUTYLCYCLOHEXANECARBOXYLATE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE;

BONE MASS; CONFERENCE PAPER; DRUG IMPLANT; HORMONE SUBSTITUTION; HYPOGONADOTROPIC HYPOGONADISM; PRIORITY JOURNAL;

ANIMALS; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; GONADAL STEROID HORMONES; GONADOTROPINS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; INFERTILITY, MALE; MALE; TESTOSTERONE;

EID: 0034732279     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(99)00227-0     Document Type: Conference Paper

References (120)

1. Adamkiewicz M., Zgliczynski S., Slowinska-Srzednicka J., Jeske W., Rabijewski M., Pietrzyk E., Srzednicki M., Sadowski Z. The relationship between plasma androgens, insulin, coagulation and fibrinolytic factors in men with coronary arteriosclerosis. Aging Male. 1:1998;270-279.
2. Albano C., Smitz J., Camus M., Bennink H.C., Van Steirteghem A.C., Devroey P. Pregnancy and birth in an in-vitro fertilization cycle after controlled ovarian stimulation in a woman with a history of allergic reaction to human menopausal gonadotrophin. Hum. Reprod. 11:1996;1632-1634.
3. Anderson R.A., Wu F.C. Comparison between testosterone enanthate-induced azoospermia and oligospermia in a male contraceptive study. II. Pharmacokinetics and pharmacodynamics of once weekly administration of testosterone enanthate. J. Clin. Endocrinol. Metab. 81:1996;896-901.
4. Atkinson L.E., Chang Y.L., Snyder P.J. Testosterone. action, deficiency, substitution. Nieschlag E., Behre H.M. Long-term Experience With Testosterone Replacement Through Scrotal Skin. 2nd ed. 1998;365-388 Springer, Berlin.
5. Bals-Pratsch M., Knuth U.A., Yoon Y.D., Nieschlag E. Transdermal testosterone substitution therapy for male hypogonadism. Lancet. 2:1986;943-946.
6. Bals-Pratsch M., Langer K., Place V.A., Nieschlag E. Substitution therapy of hypogonadal men with transdermal testosterone over one year. Acta Endocrinol. (Copenh.). 118:1988;7-13.
7. Bals-Pratsch M., Knuth U.A., Honigl W., Klein H.M., Bergmann M., Nieschlag E. Pulsatile GnRH-therapy in oligozoospermic men does not improve seminal parameters despite decreased FSH levels. Clin. Endocrinol. (Oxf.). 30:1989;549-560.
8. Barrio R., de Luis D., Alonso M., Lamas A., Moreno J.C. Induction of puberty with human chorionic gonadotropin and follicle-stimulating hormone in adolescent males with hypogonadotropic hypogonadism. Fertil. Steril. 71:1999;244-248.
9. Behre H.M., Nieschlag E. Comparative pharmacokinetics of testosterone esters. Nieschlag E., Behre H.M. Testosterone. Action, Deficiency, Substitution. 2nd ed. 1998;329-348 Springer, Berlin.
10. Behre H.M., Bohmeyer J., Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin. Endocrinol. (Oxf.). 40:1994;341-349.
11. Behre H.M., Kliesch S., Schädel F., Nieschlag E. Clinical relevance of scrotal and transcrectal ultrasonography in andrological patients. Int. J. Androl. 18:1995;27-31.
12. Behre H.M., Baus S., Kliesch S., Keck C., Simoni M., Nieschlag E. Potential of testosterone buciclate for male contraception: endocrine differences between responders and non-responders. J. Clin. Endocrinol. Metab. 80:1995;2394-2403.
13. Behre H.M., Yeung C.H., Nieschlag E. Diagnosis of Male Infertility and Hypogonadism. Nieschlag E., Behre H.M. Andrology, Male Reproductive Health and Dysfunction. 1997;87-111 Springer, Berlin.
14. Behre H.M., Simoni M., Nieschlag E. Strong association between serum levels of leptin and testosterone in men. Clin. Endocrinol. (Oxf.). 47:1997;237-240.
15. Behre H.M., Kliesch S., Leifke E., Link T.M., Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J. Clin. Endocrinol. Metab. 82:1997;2386-2390.
16. Behre H.M., Abshagen K., Oettel M., Hübler D., Nieschlag E. Intramuscular injection of testosterone undecanoate for the treatment of mal hypogonadism: phase I studies. Eur. J. Endocrinol. 140:1999;414-419.
17. Behre, H.M., von Eckardstein, S., Kliesch, S., Nieschlag, E., 1999b. Long-term substitution therapy of hypogondadal men with transscrotal testosterone over 7-10 years. Clin. Endocrinol., 50, 629-635.
18. Bhasin S., Swerdloff R.S., Steiner B., Peterson M.A., Meridores T., Galmirini M., Pandian M.R., Goldberg R., Berman N. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men. J. Clin. Endocrinol. Metab. 74:1996;75-83.
19. Bhasin S., Bagatell C.J., Bremner W.J., Plymate S.R., Tenover J.L., Korenmann S.G., Nieschlag E. Therapeutic perspective: issues in testosterone replacement in older men. J. Clin. Endocrinol. Metab. 83:1998;3435-3448.
20. Biffoni M., Marcucci I., Ythier A., Eshkol A. Effects of urinary gonadotrophin preparations on human in-vitro immune function. Hum. Reprod. 13:1998;2430-2434.
21. Blumenfeld Z., Frisch L., Conn P.M. Gonadotropin-releasing hormone (GnRH) antibodies formation in hypogonadotropic azoospermic men treated with pulsatile GnRH-diagnosis and possible alternative treatment. Fertil. Steril. 50:1988;622-629.
22. Büchter D., Behre H.M., Kliesch S., Nieschlag E. Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases. Eur. J. Endocrinol. 139:1998;298-303.
23. Burgues S., Calderon M.D. Subcutaneous self-administration of highly purified follicle stimulating hormone and human chorionic gonadotropin for the treatment of mal hypogonadotropic hypogonadism. Spanish Collaborative Group on Male Hypogonadotropic Hypogonadism. Hum. Reprod. 12:1997;980-986.
24. Burris A.S., Rodbard H.W., Winters S.J., Sherins R.J. Gonadotropin therapy in men with isolated hypogonadotropic hypogonadism: the response to human chorionic gonadotropin is predicted by initial testicular size. J. Endocrinol. Metab. 66:1988;1144-1151.
25. Burris A.S., Clark R.V., Vantman D.J., Sherins R.J. A low sperm concentration does not preclude fertility in men with isolated hypogonadotropic hypogonadism after gonadotropin therapy. Fertil. Steril. 50:1988;343-347.
26. Carani C., Granata A.R., De Rosa M., Garau C., Zarrilli S., Paesano L., Colao A., Marrama P., Lombardi G. The effect of chronic treatment with GH on gonadal function in men with isolated GH deficiency. Eur. J. Endocrinol. 140:1999;224-230.
27. Carani C., Mantovani R., Procopio M., Rio G.D., Rossetto R., Granata A.R. GH/IGF-I axis in azoospermia in primary and secondary hypogonadism: a study before and during replacement therapy. Int. J. Androl. 22:1999;184-189.
28. Christiansen K. Behavioural correlates of testosterone. Nieschlag E., Behre H.M. Testosterone. Action, Deficiency, Substitution. 2nd ed. 1998;107-142 Springer, Berlin.
29. Claustrat B., David L., Faure A., Francois R. Development of anti-human chorionic gonadotropin antibodies in patients with hypogonadotropic hypogonadism. A study of four patients. J. Clin. Endocrinol. Metab. 57:1983;1041-1047.
30. Clopper R.R., Voorhess M.L., MacGillivray M.H., Lee P.A., Mills B. Psychosexual behavior in hypopituitary men: a controlled comparison of gonadotropin and testosterone replacement. Psychoneuroendocrinology. 18:1993;149-161.
31. Coert A., Geelen J., de Visser J., van der Vies J. The pharmacology and metabolism of testosterone undecanoate (TU), a new orally active androgen. Acta Endocrinol. 79:1975;789-800.
32. Colao A., Marzullo P., Spiezia S., Ferone D., Giaccio A., Cerbone G., Pivonello R., Di Somma C., Lombardi G. Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects. J. Clin. Endocrinol. Metab. 84:1999;1986-1991.
33. Conway A.J., Boylan L.M., Howe C., Ross G., Handelsman D.J. Randomized clinical trial of testosterone replacement therapy in hypogonadal men. Int. J. Androl. 11:1988;247-264.
34. Cummings D.E., Kumar N., Bardin C.W., Sundaram K., Bremner W.J. Prostate-sparing effects in primates of the potent androgen 7α-methyl-19-nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception. J. Clin. Endocrinol. Metab. 83:1998;4212-4219.
35. Daggett P.R., Wheeler M.J., Nabarro J.D. Oral testosterone, a reappraisal. Horm. Res. 9:1978;121-129.
36. Danner C., Frick G. Androgen substitution with testosterone-containing nasal drops. Int. J. Androl. 3:1980;429-431.
37. de Roux N., Young J., Brailly-Tabard S., Misrahi M., Milgrom E., Schaison G. The same molecular defects of the gonadotropin-releasing hormone receptor determine a variable degree of hypogonadism in affected kindred. J. Clin. Endocrinol. Metab. 84:1999;567-572.
38. Delemarre-van de Waal H. Induction of testicular growth and spermatogenesis by pulsatile, intravenous administration of gonadotrophin-releasing hormone in patients with hypogonadotrophic hypogonadism. Clin. Endocrinol. 38:1993;473-480.
39. Deshmukh U.S., Talwar G.P., Gupta S.K. Antibody response against three epitopic domains on human chorionic gonadotropin (hCG) in women and rodents immunized with a β hCG-based immunocontraceptive vaccine. J. Clin. Immunol. 14:1994;162-168.
40. Dobs A.S., Hoover D.R., Chen M.C., Allen R. Pharmacokinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: a pilot study. J. Clin. Endocrinol. Metab. 83:1998;33-39.
41. Efficacy and safety of highly purified urinary follicle-stimulating hormone with human chorionic gonadotropin for treating men with isolated hypogonadotropic hypogonadism. Fertil. Steril. 70:1998;256-262.
42. Finkelstein J.S. Androgens and bone metabolism. Nieschlag E., Behre H.M. Testosterone. Action, Deficiency, Substitution. 2nd ed. 1998;187-207 Springer, Berlin.
43. Finkel, D.M., Phillips, J.L., Snyder, P.J. 1985. Stimulation of spermatogenesis by gonadotropins in men with hypogonad otropic hypogonadism. New Eng. J. Med. 12, 651-655.
44. Frick J., Jungwirth A., Rovan E. Androgens and the prostate. Nieschlag E., Behre H.M. Testosterone. Action, Deficiency, Substitution. 2nd ed. 1998;260-291 Springer, Berlin.
45. Gluud C., Bahnsen M., Bennett P., Dietrichson O., Henriksen J.H., Johnsen S.G., Svendson L.B., Brodthagen U.A., Juhl E. Oral testosterone load related to liver function in men with alcoholic liver cirrhosis. Scand. J. Gastroenterol. 18:1993;391-396.
46. Gooren L.J. A ten-year safety study of the oral androgen testosterone undecanoate. J. Androl. 15:1994;212-215.
47. Gromoll J., Simoni M., Nieschlag E. An activating mutation of the follicle-stimulating hormone receptor autonomously sustains spermatogenesis in a hypophysectomized man. J. Clin. Endocrinol. Metab. 81:1996;1367-1370.
48. Hajjar R.R., Kaiser F.E., Morley J.E. Outcomes of long term testosterone replacement in older hypogonadal males: a retrospective analysis. J. Clin. Endocrinol. Metab. 82:1997;3793-3796.
49. Handelsman D.J. Clinical pharmacology of testosterone pellet implants. Nieschlag E., Behre H.M. Testosterone. Action, Deficiency, Substitution. 2nd ed. 1998;349-364 Springer, Berlin.
50. Handelsman D.J., Conway A.J., Boylan L.M. Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J. Clin. Endocrinol. Metab. 71:1990;216-222.
51. Handelsman D.J., Mackey M.A., Howe C., Turner L., Conway A.J. An analysis of testosterone implants for androgen replacement therapy. Clin. Endocrinol. (Oxf.). 47:1997;311-316.
52. Happ J., Ditscheid W., Krause U. Pulsatile gonadotropin-releasing hormone therapy in male patients with Kallmann's syndrome or constitutional delay of puberty. Fertil. Steril. 43:1985;599-608.
53. Janowski J.S., Oviatt S.K., Orwoll E.S. Testosterone influences spatial cognition in older men. Behav. Neurosci. 108:1994;325-332.
54. Jockenhövel F., Vogel E., Kreutzer M., Reinhardt W., Lederbogen S., Reinwein D. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men. Clin. Endocrinol. (Oxf.). 45:1996;61-71.
55. Jockenhövel F., Vogel E., Reinhardt W., Reinwein D. Effects of various modes of androgen substitution therapy on erythropoiesis. Eur. J. Med. Res. 2:1997;293-298.
56. Jockenhövel F., Blum W.F., Vogel E., Englaro P., Müller-Wieland D., Reinwein D., Rascher W., Krone W. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men. J. Clin. Endocrinol. Metab. 82:1997;2510-2513.
57. Jockenhövel F., Bullmann C., Schubert M., Vogel E., Reinhardt W., Reinwein D., Müller-Wieland D., Krone W. Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. Metabolism. 48:1999;590-596.
58. Jones T.H., Darne J.F. Self-administered subcutaneous human menopausal gonadotropin for the stimulation of testicular growth and the initiation of spermatogenesis in hypogonadotropic hypogonadism. Clin. Endocrinol. 38:1993;203-208.
59. Jordan W.P. Allergy and topical irritation associated with transdermal testosterone administration: a comparison of scrotal and non-scrotal transdermal systems. Am. J. Contact Dermat. 8:1997;108-113.
60. Kamischke, A., Nieschlag, E., 1999. Analysis of medical treatment of male infertility. Hum. Reprod. 14 (suppl. 1), 1-23.
61. Kamischke A., Behre H.M., Bergmann M., Simoni M., Schäfer T., Nieschlag E. Recombinant human follicle stimulating hormone for treatment of male idiopathic infertility: a randomized, double-blind, placebo-controlled, clinical trial. Hum. Reprod. 13:1998;596-603.
62. Kaufman M., Vermeulen A. Androgens in male senescence. Nieschlag E., Behre H.M. Testosterone. Action, Deficiency, Substitution. 2nd ed. 1998;437-471 Springer, Berlin.
63. Kliesch S., Behre H.M., Nieschlag E. Recombinant human follicle-stimulating hormone and human chorionic gonadotropin for induction of spermatogenesis in a hypogonadotropic male. Fertil. Steril. 63:1995;1326-1328.
64. Knuth U.A., Honigl W., Bals-Pratsch M., Schleicher G., Nieschlag E. Treatment of severe oligospermia with human chorionic gonadotropin/human menopausal gonadotropin: a placebo-controlled, double blind trial. J. Clin. Endocrinol. Metab. 65:1987;1081-1087.
65. Kumar N., Suvisaari J., Tsong Y.Y., Aguillaume C., Bardin C.W., Lahteenmaki P., Sundaram K. Pharmacokinetics of 7-α-methyl-19-nortestosterone in men and cynomolgus monkeys. J. Androl. 18:1997;352-358.
66. Laml T., Obruca A., Fischl F., Huber F.C. Recombinant luteinizing hormone in ovarian hyperstimulation after stimulation failure in normogonadotropic women. Gynecol. Endocrinol. 13:1999;98-103.
67. Leifke E., Korner H.C., Link T.M., Behre H.M., Peters P.E., Nieschlag E. Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle area in hypogonadal men. Eur. J. Endocrinol. 38:1998;51-58.
68. Lejeune H., Sanchez P., Chuzel F., Langlois D., Saez J.M. Time-course effects of human recombinant luteinizing hormone on porcine Leydig cell specific differentiated functions. Moll. Cell. Endocrinol. 25:1998;59-69.
69. Levalle O., Zylbersztein C., Aszpis S., Aquilano D., Terradas C., Colombani M., Aranda C., Scaglia H. Recombinant human follicle-stimulating hormone administration increases testosterone production in men, possibly by a Sertoli cell-secreted non-steroid factor. J. Clin. Endocrinol. Metab. 83:1998;3973-3976.
70. Liu L., Banks S.M., Barnes K.M., Sherins R.J. Two-year comparison of testicular responses to pulsatile gonadotropin-releasing hormone and exogenous gonadotropins from the inception of therapy in men with isolated hypogonadotropic hypogonadism. J. Clin. Endocrinol. Metab. 67:1988;1140-1145.
71. Liu P.Y., Turner L., Rushford D., McDonald J., Baker H.W., Conway A.J., Handelsman D.J. Efficacy and safety of recombinant human follicle stimulating hormone (Gonal-F) with urinary human chorionic gonadotrophin for induction of spermatogenesis and fertility in gonadotrophin-deficient men. Hum. Reprod. 14:1999;1540-1545.
72. Mannaerts B., Fauser B., Lahlou N., Harlin J., Shoham Z., Bennink H.C., Bouchard P. Serum hormone concentrations during treatment with multiple rising doses of recombinant follicle stimulating hormone (Puregon) in men with hypogonadotropic hypogonadism. Fertil. Steril. 65:1996;406-410.
73. McCrohon J.A., Jessup W., Handelsman D.J., Celermajer D.S. Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1. Circulation. 99:1999;2317-2322.
74. Meikle A.W. A permeation-enhanced non-scrotal testosterone transdermal system for the treatment of male hypogonadism. Nieschlag E., Behre H.M. Testosterone. Action, Deficiency, Substitution. 2nd ed. 1998;389-422 Springer, Berlin.
75. Meikle A.W., Arver S., Dobs A.S., Sanders S.W., Rajaram L., Mazer N.A. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site - a clinical research center study. J. Clin. Endocrinol. Metab. 81:1996;1832-1840.
76. Meikle A.W., Wilson D.E., Boike S.C., Fairless A.J., Etheredge R.C., Jorkarsky D.K. A study to assess the bioequivalence of Androderm (2×2.5 mg patches) and a newly formulated testosterone transdermal system (1×5 mg patch). Endocrine Soc. 79th Annual Meeting. 215:1997;211-321.
77. Morales A., Johnston B., Heaton J.P., Lundie M. Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes. J. Urol. 157:1997;849-854.
78. Morley J.E., Kaiser F.E., Perry H.M. 3rd, Patrick P., Morley P.M., Stauber P.M., Vellas B., Baumgartner R.N., Garry P.J. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism. 46:1997;410-413.
79. Mougdal N.R., Sairam M.R. Is there a true requirement for follicle-stimulating hormone in promoting spermatogenesis and fertility in primates? Hum. Reprod. 13:1998;916-919.
80. Mougdal N.R., Murthy G.S., Prasanna Kumar K.M., Martin F., Suresh R., Medhamurthy R., Patil S., Sehgal S., Saxena B.N. Responsiveness of human male volunteers to immunization with ovine follicle stimulating hormone vaccine: results of a pilot study. Hum. Reprod. 12:1997;457-463.
81. Nankin H.R. Hormone kinetics after intramuscular testosterone cypionate. Fertil. Steril. 47:1987;1004-1009.
82. Nieschlag, E., 1998. If testosterone, which testosterone? Which androgen regimen should be used for supplementation in older men? Formulation, dosing, and monitoring issues. In: Bhasin, S., Bagatell, C.J., Bremner, W.J., Plymate, S.R., Tenover, J.L., Korenmann, S.G., Nieschlag, E. (Eds.), Therapeutic Perspective: Issues in Testosterone Replacement in Older Men. J. Clin. Endocrinol. Metab. 83, 3443-3445.
83. Nieschlag E., Behre H.M. Andrology, Male Reproductive Health and Dysfunction. 1997;Springer, Berlin.
84. Nieschlag E., Behre H.M. Pharmacology and clinical uses of testosterone. Nieschlag E., Behre H.M. Testosterone. Action, Deficiency, Substitution. 2nd ed. 1998;294-328 Springer, Berlin.
85. Nieschlag E., Cüppers E.J., Wiegelmann W., Wickings E.J. Bioavailability and LH suppressing effect of different testosterone preparations in normal and hypogonadal men. Horm. Res. 7:1976;138-145.
86. Nieschlag E., Bernitz S., Topert M. Antigenicity of human chorionic gonadotrophin preparations in men. Clin. Endocrinol. (Oxf.). 16:1982;483-488.
87. Nieschlag, E., Simoni, M., Gromoll, J., Weinbauer, G.F., 1999a. Role of FSH in the regulation of spermatogenesis: clinical aspects. Clin. Endocrinol., 51, 139-146.
88. Nieschlag, E., Büchter, D., von Eckardstein, S., Abshagen, K., Behre, H.M., 1999b. Repeated intramuscular injections of testosterone undecanoate for substitution therapy of hypogonadal men. Clin. Endocrinol., 51, 1-7.
89. Partsch C.J., Weinbauer G.F., Fang R., Nieschlag E. Injectable testosterone undecanoate has more favourable pharmacokinetics and pharmacodynamics than testosterone enanthate. Eur. J. Endocrinol. 132:1995;514-519.
90. Philip M., Arbelle J.E., Segev Y., Parvari R. Male hypogonadism due to a mutation in the gene for the β-subunit of follicle-stimulating hormone. NEJM. 338:1998;1729-1732.
91. Recombinant follicle stimulating hormone: development of the first biotechnology product for the treatment of infertility. Hum. Reprod. Update. 4:1998;862-881.
92. Redfearn A., Hughes E.G., O'Connor M., Dolovich J. Delayed-type hypersensitivity to human gonadotropin: case report. Fertil. Steril. 64:1995;855-856.
93. Rolf C., Gottschalk I., Behre H.M., Rauch C., Thyroff U., Nieschlag E. Pharmacokinetics of new testosterone transdermal therapeutic systems in gonadotropin-releasing hormone antagonist-suppressed normal men. Exp. Clin. Endocrinol. Diab. 107:1999;63-69.
94. Saal W., Happ J., Cordes U., Baum R.P., Schmidt M. Subcutaneous gonadotropin therapy in male patients with hypogonadotropic hypogonadism. Fertil. Steril. 56:1991;319-324.
95. Schaison G., Young J., Pholsena M., Nahoul K., Couzinet B. Failure of combined follicle-stimulating hormone-testosterone administration to initiate and/or maintain spermatogenesis in men with hypogonadotropic hypogonadism. J. Clin. Endocrinol. Metab. 77:1993;1545-1549.
96. Schopohl J. Pulsatile gonadotropin releasing hormone versus gonadotropin treatment of hypothalamic hypogonadism in males. Hum. Reprod. 8(Suppl. 2):1993;175-179.
97. Schulte-Beerbühl M., Nieschlag E. Comparison of testosterone, dihydrotestosterone, luteinizing hormone and follicle-stimulating hormone in serum after injection of testosterone enanthate and testosterone cypionate. Fertil. Steril. 33:1980;201-203.
98. Schürmeyer T., Nieschlag E. Comparative pharmacokinetics of testosterone enanthate and testosterone cyclohexanecarboxylate as assessed by serum and salivary testosterone levels in normal men. Int. J. Androl. 7:1984;181-187.
99. Singh M., Das S.K., Suri S., Singh O., Talwar G.P. Regain of fertility and normality of progeny born during below protective threshold antibody titers in women immunized with the HSD-hCG vaccine. Am. J. Reprod. Immunol. 39:1998;395-398.
100. Sjogren I., Ekvarn S., Zuhlke U., Vogel F., Bee W., Weinbauer G.F., Nieschlag E. Lack of effects of recombinant human GH on spermatogenesis in the adult cynomolgus monkey (Macaca fascicularis). Eur. J. Endocrinol. 140:1999;350-357.
101. Slabbekoorn D., van Goozen S.H., Megens J., Gooren L.J., Cohen-Kettenis P.T. Activating effects of cross-sex hormones on cognitive functioning: a study of short-term and long-term effects in transsexuals. Psychoneuroendocrinology. 24:1999;423-447.
102. Sokol R.Z., McClure R.D., Peterson M., Swerdloff R.S. Gonadotropin therapy failure secondary to human chorionic gonadotropin-induced antibodies. J. Clin. Endocrinol. Metab. 52:1981;929-932.
103. Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology. 43:1994;284-292.
104. Stuenkel C.A., Dudley R.E., Yen S.S. Sublingual administration of testosterone-hydroxypropyl-β-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men. J. Clin. Endocrinol. Metab. 72:1991;1054-1059.
105. Suvisaari J., Sundaram K., Noe G., Kumar N., Aguillaume C., Tsong Y.Y., Lahteenmaki P., Bardin C.W. Pharmacokinetics and pharmacodynamics of 7-α-methyl-19-nortestosterone after intramuscular administration in healthy men. Hum. Reprod. 12:1997;967-973.
106. Thau R.B., Goldstein M., Yamamoto Y., Burrow G.N., Phillips D., Bardin C.W. Failure of gonadotropin therapy secondary to chorionic gonadotropin-induced antibodies. J. Clin. Endocrinol. Metab. 66:1988;862-867.
107. Vermeulen A., Verdonck G. Representatives of a single point plasma testosterone level for the long term hormonal milieu in men. J. Clin. Endocrinol. Metab. 74:1992;939-942.
108. Vicari E., Mongioi A., Calogero A.E., Moncada M.L., Sidoti G., Polosa P., D'Agata R. Therapy with human chorionic gonadotrophin alone induces spermatogenesis in men with isolated hypogonadotrophic hypogonadism - long-term follow-up. Int. J. Androl. 15:1992;320-329.
109. von Eckardstein A. Androgens, cardiovascular risk factors and atherosclerosis. Nieschlag E., Behre H.M. Testosterone. Action, Deficiency, Substitution. 2nd ed. 1998;230-257 Springer, Berlin.
110. von Eckardstein S., Nieschlag E. Pharmacology, pharmacokinetics and effects/side-effects of different androgen preparations. The Aging Male. 1:1998;28-34.
111. Wang C., Alexander G., Berman N., Salehian B., Davidson T., McDonald V., Steiner B., Hull L., Callegari C., Swerdloff R.S. Testosterone replacement therapy improves mood in hypogonadal men - a clinical research center study. J. Clin. Endocrinol. Metab. 81:1996;3578-3583.
112. Wang C., Eyre R., Clark D., Kleinberg C., Newman I., Veldhuis R. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption and increases bone formation markers in hypogonadal men - a clinical research center study. J. Clin. Endocrinol. Metab. 81:1996;3654-3662.
113. Wang, C., Davidson, T., Berman, N., Steiner, B., Hull, L., Baravarian, S., Dudley, R.E., Faulkner, S., Swerdloff, R.S., 1998. Pharmacokinetics of transdermal testosterone gel in hypogonadal men. Abstracts for the 80th Annual Meeting of the Endocrine Society at New Orleans, June 24-27, 1998, p. 265.
114. Wang L.Z. The therapeutic effect of domestically produced testosterone undecanoate in Klinefelter syndrome. New Drugs Market. 8:1991;28-32.
115. Weinbauer G.F., Marshall G.R., Nieschlag E. New injectable testosterone ester maintains serum testosterone of castrated monkeys in the normal range for four months. Acta Endocrinol. 113:1986;128-132.
116. Winkler U.H. Effects of androgens on haemostasis. Maturitas. 24:1996;147-155.
117. World Health Organization, Nieschlag, E., Wang, C., Handelsman, D.J., Swerdloff, R.S., Wu, F., Einer-Jensen, N., Waites, G., 1992. Guidelines for the use of androgens. WHO, Geneva.
118. WHO Laboratory Manual for the Examination of Human Semen and Sperm-Cervical Mucus Interaction. 4th ed. 1999;Cambridge University Press, Cambridge.
119. Wu F.C.W., Farley T.N.M., Peregoudow A., Waites G.M.H. Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organisation Task Force on Methods for the Regulation of Male Fertility. Fertil. Steril. 65:1996;626-636.
120. Zgliczynski S., Ossowski M., Slowinska-Srzednicka J., Brzezinska A., Zgliczynski W., Soszynski P. Effects of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis. 121:1996;35-43.